# A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

> **NCT03519295** · PHASE2 · COMPLETED · sponsor: **GERCOR - Multidisciplinary Oncology Cooperative Group** · enrollment: 97 (actual)

## Conditions studied

- Anal Cancer

## Interventions

- **DRUG:** MPDL3280A
- **DRUG:** mDCF

## Key facts

- **NCT ID:** NCT03519295
- **Lead sponsor:** GERCOR - Multidisciplinary Oncology Cooperative Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-03
- **Primary completion:** 2023-02-07
- **Final completion:** 2023-09-20
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2025-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03519295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03519295, "A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03519295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*